▁Introduction 10.375
: 6.515625
<0x0A> 3.95703125
In 4.58203125
▁recent 4.8671875
▁years 0.383544921875
, 0.311767578125
▁substantial 8.4296875
▁adv 3.123046875
anc 2.259765625
ements 0.0001627206802368164
▁have 0.44775390625
▁been 0.0504150390625
▁made 0.07098388671875
▁in 0.133056640625
▁the 0.6494140625
▁treatment 3.8359375
▁of 0.0975341796875
▁mel 5.3828125
an 0.0143585205078125
oma 0.11285400390625
▁- 7.23828125
▁a 1.703125
▁highly 3.869140625
▁ag 0.73291015625
gress 0.0001461505889892578
ive 0.0003838539123535156
▁form 1.044921875
▁of 0.0026950836181640625
▁skin 0.0982666015625
▁cancer 0.00635528564453125
. 0.58837890625
▁Im 6.953125
m 2.03515625
une 0.357177734375
▁check 0.234375
point 0.02642822265625
▁in 0.2342529296875
hib 0.0001919269561767578
itors 0.1629638671875
▁and 4.28125
▁adj 6.8359375
uv 0.0195465087890625
ant 0.00365447998046875
▁ther 0.57763671875
ap 0.46337890625
ies 0.00034165382385253906
▁have 0.69287109375
▁emer 4.63671875
ged 0.0003864765167236328
▁as 0.10858154296875
▁ground 7.703125
bre 0.36279296875
aking 0.0005221366882324219
▁treat 2.087890625
ments 0.00026035308837890625
▁that 1.8603515625
▁offer 3.712890625
▁the 2.658203125
▁potential 1.2177734375
▁for 1.099609375
▁long 1.908203125
- 0.056671142578125
term 0.1651611328125
▁rem 2.01953125
ission 0.58984375
. 1.56640625
▁This 3.70703125
▁ess 8.4453125
ay 0.00830841064453125
▁expl 2.8046875
ores 0.001922607421875
▁the 0.447021484375
▁imp 5.23828125
lications 0.12646484375
▁of 0.158203125
▁these 1.0419921875
▁ther 3.291015625
ap 0.004901885986328125
ies 0.00013267993927001953
▁for 0.90966796875
▁patients 2.068359375
▁at 5.28125
▁different 2.720703125
▁stages 0.41552734375
▁of 0.07757568359375
▁mel 1.6748046875
an 0.00020241737365722656
oma 0.00394439697265625
, 1.3935546875
▁foc 4.578125
using 0.02264404296875
▁on 0.216796875
▁their 2.98828125
▁impact 2.560546875
▁on 0.2198486328125
▁impro 6.6328125
ving 0.0006985664367675781
▁surv 1.6669921875
ival 0.0222930908203125
▁rates 1.6318359375
. 1.123046875
▁To 6.03515625
▁further 4.01171875
▁illustrate 3.33984375
▁these 2.5703125
▁adv 3.1328125
anc 0.7021484375
ements 0.00013828277587890625
, 0.16455078125
▁the 1.478515625
▁case 5.40625
▁of 0.97412109375
▁Mr 7.3203125
. 0.323974609375
▁B 3.74609375
, 1.806640625
▁a 0.47900390625
▁mel 2.716796875
an 0.00013720989227294922
oma 0.0038776397705078125
▁patient 0.291015625
, 1.1953125
▁will 1.75
▁be 0.0496826171875
▁used 1.7822265625
▁as 1.09375
▁an 1.328125
▁example 0.2254638671875
. 0.4521484375
<0x0A> 0.576171875
Body 8.5078125
: 2.802734375
<0x0A> 1.9580078125
The 2.185546875
▁introduction 5.015625
▁of 1.0029296875
▁imm 0.97900390625
une 0.2430419921875
▁check 0.0182037353515625
point 0.02862548828125
▁in 0.044708251953125
hib 0.00010609626770019531
itors 0.0279998779296875
, 2.88671875
▁such 1.5703125
▁as 0.0036525726318359375
▁p 1.7421875
emb 0.0011692047119140625
rol 0.002170562744140625
iz 0.002773284912109375
um 0.0017757415771484375
ab 0.00026988983154296875
▁and 1.216796875
▁n 0.0592041015625
iv 0.001216888427734375
ol 0.00043892860412597656
um 0.0008902549743652344
ab 0.0008454322814941406
, 0.07403564453125
▁marks 5.7109375
▁a 0.32080078125
▁significant 1.7548828125
▁shift 1.6708984375
▁in 0.10076904296875
▁mel 2.064453125
an 0.0003566741943359375
oma 0.00299072265625
▁treatment 0.283447265625
. 0.410888671875
▁These 1.173828125
▁in 4.3984375
hib 0.004337310791015625
itors 0.0223388671875
▁target 1.9130859375
▁specific 3.259765625
▁check 2.9453125
points 0.452880859375
▁on 2.029296875
▁imm 1.818359375
une 0.003322601318359375
▁cells 0.15625
, 0.890625
▁effectively 5.04296875
▁blocking 0.96142578125
▁the 1.2529296875
▁signals 4.26171875
▁that 0.461181640625
▁prevent 3.455078125
▁T 3.181640625
- 0.87451171875
cell 0.0237579345703125
s 0.11663818359375
▁( 4.30078125
a 1.03515625
▁type 0.1409912109375
▁of 0.0008082389831542969
▁imm 0.7470703125
une 0.006473541259765625
▁cell 0.06048583984375
) 0.09710693359375
▁from 0.078125
▁attack 0.90625
ing 3.457069396972656e-05
▁cancer 1.259765625
▁cells 0.34033203125
. 0.13232421875
▁As 3.056640625
▁a 0.1568603515625
▁result 0.018157958984375
, 0.06939697265625
▁the 2.541015625
▁body 2.62890625
' 0.452880859375
s 0.00022268295288085938
▁imm 0.6181640625
une 0.00502777099609375
▁system 0.06890869140625
▁is 0.6884765625
▁react 5.1875
iv 0.0012226104736328125
ated 0.00013887882232666016
, 0.6044921875
▁en 4.71484375
han 2.033203125
cing 2.7418136596679688e-06
▁its 1.1142578125
▁ability 0.115478515625
▁to 0.000682830810546875
▁fight 1.4912109375
▁mel 3.12109375
an 5.328655242919922e-05
oma 0.011322021484375
. 0.8837890625
▁Several 5.2890625
▁studies 1.12890625
▁have 0.068603515625
▁reported 4.53515625
▁remarkable 5.96484375
▁response 3.5
▁rates 0.00383758544921875
▁to 3.353515625
▁imm 1.125
une 0.06768798828125
▁check 0.05413818359375
point 0.0022125244140625
▁in 0.030303955078125
hib 3.0279159545898438e-05
itors 0.1673583984375
, 1.2607421875
▁with 0.42431640625
▁a 2.77734375
▁subset 7.9609375
▁of 0.09478759765625
▁patients 0.118896484375
▁ach 0.92138671875
ieving 7.855892181396484e-05
▁dur 1.34765625
able 0.001071929931640625
▁long 4.30859375
- 0.00872039794921875
term 0.0034923553466796875
▁rem 0.2034912109375
ission 0.450927734375
. 0.47705078125
<0x0A> 1.205078125
Pat 4.75
ients 0.436279296875
▁with 1.375
▁advanced 1.5810546875
▁or 3.44921875
▁met 0.188720703125
ast 0.00018930435180664062
atic 0.0012140274047851562
▁mel 0.0728759765625
an 0.00013172626495361328
oma 0.002925872802734375
▁have 1.8232421875
▁particularly 5.78515625
▁benef 4.23828125
ited 0.208251953125
▁from 0.00507354736328125
▁imm 1.673828125
une 0.07965087890625
▁check 0.0183258056640625
point 0.0018224716186523438
▁in 0.01605224609375
hib 8.571147918701172e-05
itors 0.1683349609375
. 0.8017578125
▁Research 4.703125
, 7.84765625
▁including 1.650390625
▁clin 3.1640625
ical 0.0009984970092773438
▁tri 0.163330078125
als 4.5299530029296875e-06
, 0.81787109375
▁consist 7.6328125
ently 4.2319297790527344e-05
▁demonstrate 2.5234375
▁improved 3.37109375
▁overall 1.5849609375
▁surv 0.050018310546875
ival 0.0006108283996582031
▁rates 0.71533203125
▁and 2.07421875
▁pro 2.2109375
gression 0.002712249755859375
- 0.046875
free 0.0022430419921875
▁surv 0.004547119140625
ival 0.0013456344604492188
▁in 1.9677734375
▁patients 0.364990234375
▁treated 0.56005859375
▁with 0.003482818603515625
▁these 1.34765625
▁in 3.0859375
hib 0.00043892860412597656
itors 0.0037441253662109375
▁compared 1.642578125
▁to 0.408203125
▁traditional 3.423828125
▁chem 1.6318359375
other 0.015960693359375
apy 0.1934814453125
. 1.2626953125
▁For 2.95703125
▁instance 2.220703125
, 0.0026836395263671875
▁a 0.9501953125
▁study 1.82421875
▁published 1.14453125
▁in 0.04486083984375
▁the 1.654296875
▁New 0.8359375
▁England 0.0006275177001953125
▁Journal 0.0019855499267578125
▁of 0.006744384765625
▁Medicine 0.001251220703125
▁reported 1.7734375
▁a 1.380859375
▁median 1.0546875
▁overall 0.38330078125
▁surv 0.00510406494140625
ival 6.580352783203125e-05
▁of 0.64990234375
▁ 0.131103515625
7 3.35546875
2 3.345703125
. 0.95703125
1 2.435546875
▁months 0.0286865234375
▁in 0.66162109375
▁patients 0.09710693359375
▁receiving 2.734375
▁p 1.1123046875
emb 0.002025604248046875
rol 7.700920104980469e-05
iz 0.000583648681640625
um 0.0005536079406738281
ab 3.516674041748047e-05
, 2.4140625
▁compared 0.1593017578125
▁to 0.2196044921875
▁ 0.1910400390625
1 2.322265625
6 2.087890625
. 0.07159423828125
0 3.16015625
▁months 0.017303466796875
▁in 0.311767578125
▁those 1.1845703125
▁receiving 0.492431640625
▁chem 1.1142578125
other 0.0018262863159179688
apy 0.0012989044189453125
. 1.03515625
▁This 3.05078125
▁presents 7.83203125
▁a 0.5634765625
▁significant 0.79931640625
▁adv 5.05078125
ancement 0.0007772445678710938
, 4.0078125
▁offering 2.685546875
▁new 3.86328125
▁hope 0.1256103515625
▁to 0.98291015625
▁patients 0.223388671875
▁who 2.001953125
▁were 3.62890625
▁previously 0.0853271484375
▁faced 5.46875
▁with 0.0011463165283203125
▁limited 2.857421875
▁treatment 0.182861328125
▁options 0.01522064208984375
▁and 2.578125
▁poor 2.6015625
▁pro 0.73583984375
gn 0.0003063678741455078
osis 1.51171875
. 0.156494140625
<0x0A> 0.2105712890625
F 4.53125
ur 0.09576416015625
ther 7.164478302001953e-05
more 0.25732421875
, 0.0020294189453125
▁the 1.876953125
▁use 2.080078125
▁of 0.0009183883666992188
▁imm 0.286376953125
une 0.031524658203125
▁check 0.0174407958984375
point 0.0022411346435546875
▁in 0.00374603271484375
hib 1.4543533325195312e-05
itors 0.007213592529296875
▁as 3.685546875
▁adj 0.416259765625
uv 0.0131988525390625
ant 0.005344390869140625
▁ther 0.1026611328125
ap 1.1904296875
ies 3.3855438232421875e-05
▁in 2.20703125
▁patients 0.9716796875
▁with 0.6396484375
▁high 3.443359375
- 0.142822265625
ris 0.01513671875
k 2.3484230041503906e-05
▁mel 0.1578369140625
an 3.9696693420410156e-05
oma 0.01192474365234375
▁who 4.546875
▁have 0.6513671875
▁under 1.6884765625
g 0.0010347366333007812
one 7.140636444091797e-05
▁surg 1.28515625
ical 1.9375
▁res 0.65087890625
ection 0.01470947265625
▁has 1.1552734375
▁shown 2.416015625
▁prom 1.0888671875
ising 3.4809112548828125e-05
▁results 0.16162109375
. 0.265625
▁Ad 3.78125
j 0.03131103515625
uv 0.0007395744323730469
ant 0.0001785755157470703
▁ther 0.2734375
apy 0.330810546875
▁is 1.435546875
▁admin 3.150390625
ister 0.0001653432846069336
ed 0.0009732246398925781
▁after 0.6044921875
▁cur 4.59375
ative 0.00441741943359375
▁surg 0.7109375
ery 0.11309814453125
▁to 0.86669921875
▁eliminate 5.67578125
▁any 1.1513671875
▁remaining 0.962890625
▁und 8.140625
et 0.203369140625
ected 0.1126708984375
▁cancer 0.88623046875
▁cells 0.1279296875
▁and 1.5517578125
▁reduce 2.423828125
▁the 0.0491943359375
▁risk 0.0985107421875
▁of 0.023406982421875
▁rec 0.427001953125
urrence 0.0167083740234375
. 0.2137451171875
▁For 3.736328125
▁instance 1.2607421875
, 0.0010280609130859375
▁a 0.44384765625
▁trial 3.90234375
▁investig 5.85546875
ating 0.09027099609375
▁the 0.85009765625
▁use 0.72412109375
▁of 0.004474639892578125
▁p 0.98193359375
emb 0.0007004737854003906
rol 5.173683166503906e-05
iz 0.0010652542114257812
um 0.0007767677307128906
ab 4.7206878662109375e-05
▁as 0.58935546875
▁adj 0.2171630859375
uv 0.00267791748046875
ant 1.8596649169921875e-05
▁ther 0.0804443359375
apy 0.0008959770202636719
▁for 1.6689453125
▁patients 0.6982421875
▁with 0.2059326171875
▁stage 1.7607421875
▁III 0.62109375
▁mel 1.1337890625
an 2.193450927734375e-05
oma 0.0016489028930664062
▁demonstrated 2.251953125
▁a 0.7783203125
▁significantly 3.015625
▁increased 2.626953125
▁rec 4.66796875
urrence 0.0018835067749023438
- 0.0196533203125
free 0.00675201416015625
▁surv 0.1605224609375
ival 3.707408905029297e-05
▁among 4.6484375
▁the 4.04296875
▁treated 2.751953125
▁group 0.48681640625
▁compared 0.5634765625
▁to 0.0665283203125
▁those 1.6923828125
▁receiving 1.501953125
▁place 2.625
bo 0.0017080307006835938
. 0.66015625
▁These 2.46875
▁find 1.2412109375
ings 4.76837158203125e-07
▁highlight 3.03125
▁the 0.074462890625
▁potential 0.7626953125
▁for 1.630859375
▁imm 1.66796875
une 0.09014892578125
▁check 0.01971435546875
point 0.00154876708984375
▁in 0.005176544189453125
hib 2.6226043701171875e-05
itors 0.053497314453125
▁to 1.1982421875
▁provide 2.61328125
▁long 0.9189453125
- 0.004245758056640625
term 0.0270538330078125
▁rem 1.2216796875
ission 0.0196990966796875
▁and 2.54296875
▁improve 1.416015625
▁surv 1.5419921875
ival 0.001079559326171875
▁rates 0.2359619140625
▁in 0.95849609375
▁earlier 9.65625
▁stages 1.1279296875
▁of 0.0201263427734375
▁mel 0.182861328125
an 5.6624412536621094e-05
oma 0.0010986328125
. 0.36376953125
<0x0A> 0.1260986328125
The 2.419921875
▁imp 3.951171875
lications 0.028228759765625
▁of 0.08319091796875
▁these 0.69921875
▁adv 2.0078125
anc 0.2332763671875
ements 4.756450653076172e-05
▁are 1.8642578125
▁prof 2.953125
ound 8.106231689453125e-05
. 1.2998046875
▁Pat 2.474609375
ients 0.01390838623046875
▁diagn 3.63671875
osed 0.0002455711364746094
▁with 0.08050537109375
▁mel 1.05078125
an 6.508827209472656e-05
oma 0.0005326271057128906
▁at 1.6298828125
▁various 4.56640625
▁stages 0.04339599609375
▁now 2.005859375
▁have 0.019378662109375
▁access 1.6259765625
▁to 0.0007181167602539062
▁more 3.025390625
▁effective 0.404296875
, 3.244140625
▁target 1.2841796875
ed 0.00034618377685546875
, 4.1328125
▁and 0.0362548828125
▁personal 1.693359375
ized 0.028778076171875
▁treatment 1.03125
▁options 0.11444091796875
. 1.107421875
▁Moreover 4.2265625
, 0.0001119375228881836
▁imm 2.544921875
une 0.1097412109375
▁check 0.0183868408203125
point 0.0028324127197265625
▁in 0.0034809112548828125
hib 1.3947486877441406e-05
itors 0.0257568359375
▁have 1.2236328125
▁shown 2.921875
▁potential 3.361328125
▁in 2.171875
▁extending 3.705078125
▁surv 0.8876953125
ival 0.002834320068359375
▁rates 0.99853515625
▁even 4.90234375
▁in 0.86474609375
▁stage 6.58203125
▁IV 0.60400390625
▁mel 0.414794921875
an 3.4332275390625e-05
oma 0.007549285888671875
, 0.8505859375
▁histor 10.984375
ically 0.00014293193817138672
▁the 2.72265625
▁most 0.383544921875
▁challeng 3.591796875
ing 7.319450378417969e-05
▁to 2.369140625
▁treat 0.08074951171875
. 0.17626953125
▁This 1.8779296875
▁remarkable 7.49609375
▁progress 0.95703125
▁not 5.4609375
▁only 0.0055694580078125
▁prolong 7.8359375
s 0.0014905929565429688
▁the 1.318359375
▁lives 0.250244140625
▁of 0.0026569366455078125
▁mel 3.302734375
an 4.684925079345703e-05
oma 0.0005598068237304688
▁patients 0.006649017333984375
▁but 0.56103515625
▁also 0.06622314453125
▁impro 2.091796875
ves 0.00020456314086914062
▁their 0.79443359375
▁quality 0.15625
▁of 0.01776123046875
▁life 0.002788543701171875
▁by 1.310546875
▁reducing 1.212890625
▁the 0.767578125
▁bur 1.6103515625
den 0.037506103515625
▁of 0.055206298828125
▁traditional 8.375
▁treat 1.4716796875
ments 1.52587890625e-05
, 2.32421875
▁such 0.468017578125
▁as 0.0009675025939941406
▁chem 0.3955078125
other 0.0194091796875
apy 0.002658843994140625
. 1.30859375
<0x0A> 0.505859375
The 2.119140625
▁case 2.1953125
▁of 0.094482421875
▁Mr 0.145263671875
. 0.0140228271484375
▁B 0.087646484375
▁exempl 4.0625
ifies 0.005382537841796875
▁the 0.479736328125
▁transform 4.73046875
ative 0.11444091796875
▁impact 0.9580078125
▁of 0.27001953125
▁imm 0.45263671875
une 0.03411865234375
▁check 0.005382537841796875
point 0.0018157958984375
▁in 0.00421142578125
hib 1.430511474609375e-05
itors 0.03802490234375
▁on 1.1064453125
▁mel 0.779296875
an 6.461143493652344e-05
oma 0.0019044876098632812
▁treatment 1.115234375
. 0.16845703125
▁Mr 0.90234375
. 0.0057830810546875
▁B 0.0014362335205078125
, 0.9921875
▁diagn 3.564453125
osed 6.0439109802246094e-05
▁with 0.0350341796875
▁stage 0.8984375
▁IV 0.6259765625
▁mel 0.19384765625
an 3.337860107421875e-05
oma 0.0002009868621826172
▁and 4.87109375
▁given 4.44921875
▁a 1.595703125
▁ble 5.5234375
ak 0.019256591796875
▁pro 0.132080078125
gn 2.574920654296875e-05
osis 0.00019550323486328125
, 0.18310546875
▁comm 8.453125
enced 0.01727294921875
▁p 3.703125
emb 0.0028514862060546875
rol 9.930133819580078e-05
iz 0.00061798095703125
um 0.0009245872497558594
ab 5.316734313964844e-05
▁treatment 1.052734375
. 2.470703125
▁Rem 7.46875
ark 0.1884765625
ably 0.083984375
, 0.0025234222412109375
▁he 1.70703125
▁experienced 1.98828125
▁tum 6.375
or 0.063232421875
▁regression 0.98583984375
, 2.0859375
▁leading 1.73828125
▁to 0.0699462890625
▁a 0.77392578125
▁complete 2.03515625
▁response 0.2454833984375
▁and 1.7939453125
▁dur 3.125
able 0.004364013671875
▁long 0.3173828125
- 0.005825042724609375
term 0.0005879402160644531
▁rem 0.053619384765625
ission 0.0013189315795898438
. 0.26904296875
▁This 1.4609375
▁example 3.29296875
, 6.015625
▁among 2.998046875
▁count 5.03515625
less 1.537799835205078e-05
▁others 0.0703125
, 0.059814453125
▁demonstr 1.7275390625
ates 0.00012695789337158203
▁the 0.2427978515625
▁potential 1.794921875
▁of 0.74609375
▁imm 0.3173828125
une 0.06597900390625
▁check 0.00771331787109375
point 0.0014066696166992188
▁in 0.0038433074951171875
hib 1.049041748046875e-05
itors 0.0223236083984375
▁in 1.5546875
▁providing 3.6875
▁life 3.90625
- 0.0025844573974609375
alter 3.0859375
ing 9.02414321899414e-05
▁out 2.33203125
comes 0.0003495216369628906
▁for 0.297119140625
▁mel 1.3046875
an 4.3511390686035156e-05
oma 0.0006508827209472656
▁patients 0.00372314453125
. 0.431640625
<0x0A> 0.6181640625
Con 3.76171875
clusion 0.430908203125
: 0.396240234375
<0x0A> 3.958984375
The 1.216796875
▁adv 2.958984375
anc 0.79443359375
ements 3.528594970703125e-05
▁in 0.58984375
▁mel 1.119140625
an 0.00020015239715576172
oma 0.0008168220520019531
▁treatment 0.108642578125
▁through 4.5078125
▁the 0.375732421875
▁use 0.08575439453125
▁of 0.0021533966064453125
▁imm 0.060150146484375
une 0.008453369140625
▁check 0.00429534912109375
point 0.00464630126953125
▁in 0.0015439987182617188
hib 1.823902130126953e-05
itors 0.0041351318359375
▁and 1.51953125
▁adj 0.01114654541015625
uv 0.00232696533203125
ant 0.00028133392333984375
▁ther 0.0192718505859375
ap 0.127685546875
ies 2.09808349609375e-05
▁have 0.8076171875
▁revolution 4.28125
ized 0.004058837890625
▁patient 3.04296875
▁care 0.8916015625
. 0.355224609375
▁These 1.1123046875
▁ther 0.55810546875
ap 0.0007939338684082031
ies 3.814697265625e-06
▁offer 2.177734375
▁new 3.421875
found 7.421875
▁hope 0.02685546875
▁for 0.68212890625
▁mel 3.10546875
an 8.380413055419922e-05
oma 0.003986358642578125
▁patients 0.030029296875
▁at 1.6240234375
▁various 1.900390625
▁stages 0.00707244873046875
, 2.212890625
▁including 2.171875
▁those 0.50634765625
▁with 0.8759765625
▁advanced 1.150390625
▁or 0.32421875
▁met 0.0160675048828125
ast 2.1696090698242188e-05
atic 0.00033354759216308594
▁disease 0.1358642578125
. 0.418701171875
▁The 1.931640625
▁case 1.5478515625
▁of 0.03497314453125
▁Mr 0.0084686279296875
. 0.00524139404296875
▁B 0.004444122314453125
▁exempl 0.9033203125
ifies 0.0032672882080078125
▁the 0.1583251953125
▁potential 2.146484375
▁for 1.5322265625
▁long 2.076171875
- 0.005977630615234375
term 0.00885772705078125
▁rem 0.1475830078125
ission 0.01026153564453125
▁and 0.50146484375
▁improved 0.365234375
▁ch 11.28125
ances 0.0010976791381835938
▁of 0.37451171875
▁surv 0.08203125
ival 0.00433349609375
. 3.2265625
▁As 2.1640625
▁research 3.802734375
▁continues 0.7314453125
▁to 0.74951171875
▁enh 8.0234375
ance 9.85860824584961e-05
▁our 0.98486328125
▁understanding 0.10626220703125
▁of 0.0170745849609375
▁these 2.93359375
▁ther 0.7568359375
ap 0.00037598609924316406
ies 1.5497207641601562e-06
, 0.2783203125
▁it 2.66796875
▁is 0.36181640625
▁cru 2.5390625
cial 0.0009551048278808594
▁to 0.90673828125
▁ensure 2.828125
▁access 4.4296875
ibility 0.8154296875
, 3.28125
▁afford 1.8251953125
ability 0.0014238357543945312
, 0.006610870361328125
▁and 0.04498291015625
▁expand 9.28125
▁their 4.171875
▁use 0.6064453125
▁to 0.71435546875
▁further 3.5625
▁improve 0.28271484375
▁the 1.87890625
▁pro 4.24609375
gn 0.0106353759765625
osis 0.0311431884765625
▁and 1.873046875
▁quality 0.24658203125
▁of 0.00920867919921875
▁life 0.0130462646484375
▁for 0.213623046875
▁mel 0.63720703125
an 3.981590270996094e-05
oma 0.00043272972106933594
▁patients 0.0015134811401367188
. 0.298583984375
